Kymera Therapeutics Inc.

World Rank (Aug-2026)

2250

Market Cap (Aug-2026)

9.761 Billion USD

World Rank (Jan-05-2024)

6,735

Market Cap (Jan-05-2024)

1.510 Billion USD

World Rank (Jul-30-2023)

7,820

Market Cap (Jul-30-2023)

1.208 Billion USD

World Rank (Jan-07-2022)

5,018

Market Cap (Jan-07-2022)

2.855 Billion USD

World Rank (Jan-01-2021)

4,513

Market Cap (Jan-01-2021)

2.756 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

KYMR

Employee Count

80

Employee Count as of Date

As on 2020

Headquarters City/State

Massachusetts

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

39 Million USD

Annual Operating Income in USD

-349 Million USD

Annual Net Income in USD

-311 Million USD

Annual Results for Period Ending

For year ending December-2025

Total Assets in USD

1,743 Million USD

Total Liabilities in USD

163 Million USD

Total Equity in USD

1,580 Million USD

Balance Sheet for Period Ending

As of December-2025

Business Sector

Biotechnology

Healthcare

Biopharmaceutical

Company Website

KYMERA THERAPEUTICS, INC.

Yahoo

Yahoo @ Nasdaq

Company Profile

Kymera is a Biopharmaceutical company. It is a developing novel protein degrader therapeutics to treat disease in powerful new ways which harness the body's natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. The company annual revenue is 10.4 million USD and 67 employees as on 2019. The headquarters is in USA.

Founded Year

2015

IPO Year

2020

Stock Exchange

Nasdaq

Nasdaq Sector

Health Care

Nasdaq Industry

Medicinal Chemicals and Botanical Products